Angus DC, Barnato AE, Bell D, Bellomo R, Chong CR, Coats TJ, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 2015;41:1549–60.CrossrefWeb of SciencePubMedGoogle Scholar
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014;370:1412–21.CrossrefPubMedWeb of ScienceGoogle Scholar
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–10.PubMedCrossrefGoogle Scholar
Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized,double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:1–12.PubMedGoogle Scholar
Casteleijn E, Kuiper J, Van Rooij HC, Kamps JA, Koster JF, Van Berkel TJ. Endotoxin stimulates glycogenolysis in the liver by means of intercellular communication. J Biol Chem 1988;263:6953–5.PubMedGoogle Scholar
Nesseler N, Launey Y, Aninat C, White J, Corlu A, Pieper K, et al. Liver dysfunction is associated with long-term mortality in septic shock. Am J Respir Crit Care Med 2016;193:335–7.PubMedCrossrefGoogle Scholar
Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM. ‘Liver function tests’ on the intensive care unit: a prospective, observational study. Intensive Care Med 2009;35:1406–11.PubMedWeb of ScienceCrossrefGoogle Scholar
Jenniskens M, Langouche L, Vanwijngaerden YM, Mesotten D, Van den Berghe G. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med 2016;42:16–27.PubMedWeb of ScienceCrossrefGoogle Scholar
Lebel L. Turnover of circulating hyaluronan. Studies in man and experimental animal (dissertation). Acta Univ Ups 1989;217:1–54.Google Scholar
Berg S, Jansson I, Hesselvik FJ, Laurent TC, Lennquist S, Walther S. Hyaluronan: relationship to hemodynamics and survival in porcine injury and sepsis. Crit Care Med 1992;20:1315–21.CrossrefPubMedGoogle Scholar
Alston-Smith JP, Fraser JR, Laurent TC. Effects of endotoxin in hepatic endocytosis of hyaluronan BOOK: hepatic endocytosis of lipids and proteins. München, Germany: Zuckschwerdt, 1992.Google Scholar
Itenov TS, Kirkby NS, Bestle MH, Nilsson AC, Erlandsen EJ, Peters L, et al. Hyaluronic acid assays: turbidimetric or enzyme-based immune assay? A method comparison study. J Clin Lab Anal 2016;30:524–8.PubMedCrossrefWeb of ScienceGoogle Scholar
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048–58.Web of ScienceCrossrefPubMedGoogle Scholar
Williams JM, Greenslade JH, Chu K, Brown AF, Lipman J. Severity scores in emergency department patients with presumed infection: a prospective validation study. Crit Care Med 2016;44:539–47.CrossrefPubMedWeb of ScienceGoogle Scholar
White LE, Hassoun HT, Bihorac A, Moore LJ, Sailors RM, McKinley BA, et al. Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis. J Trauma Acute Care Surg 2013;75:432–8.Web of ScienceCrossrefGoogle Scholar
Jensen JS, Itenov TS, Thormar KM, Hein L, Mohr TT, Andersen MH, et al. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. Ann Intensive Care 2016;6:114.CrossrefPubMedWeb of ScienceGoogle Scholar
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834–40.CrossrefPubMedGoogle Scholar
Brun-Buisson C, Meshaka P, Pinton P, Vallet B, Group ES. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580–8.PubMedCrossrefGoogle Scholar
van der Laan LJ, Dopp EA, Haworth R, Pikkarainen T, Kangas M, Elomaa O, et al. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol 1999;162:939–47.PubMedGoogle Scholar
Guo L, Zheng Z, Ai J, Huang B, Li XA. Hepatic scavenger receptor BI protects against polymicrobial-induced sepsis through promoting LPS clearance in mice. J Biol Chem 2014;289:14666–73.CrossrefPubMedWeb of ScienceGoogle Scholar
Dwivedi DJ, Grin PM, Khan M, Prat A, Zhou J, Fox-Robichaud AE, et al. Differential expression of PCSK9 modulates infection, inflammation and coagulation in a murine model of sepsis. Shock 2016;46:672–80.CrossrefWeb of ScienceGoogle Scholar
Schouten M, van’t Veer C, Poulussen N, Meijers JC, Levi M, Esmon CT, et al. The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis. Thromb Res 2015;135:537–43.Web of ScienceCrossrefPubMedGoogle Scholar
About the article
Published Online: 2019-04-05
Published in Print: 2019-08-27
Data availability: The clinical and biochemical data used to support the findings of this study are restricted by the Ethics Board for the Capital Region of Denmark, KF 01-272-753, KF 11 297 287 and the Danish data protection law, in order to protect patient privacy. Data are available from the corresponding author for researchers who meet the criteria for access to confidential data. External researchers can apply the Ethics Board of the Capital Region of Denmark for access. The authors will guide and help with such an application.
Author contributions: Contributors: JUJ, TSI and JDL had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed substantially to conception and design, or acquisition of data, or analysis and interpretation of data. JUJ and JDL drafted the article. Statistical analysis: JUJ, TSI, JDL. Obtained funding: JUJ, JDL, BL. Administrative, technical, or material support: All authors. All other authors revised it critically for important intellectual content. All authors gave final approval of the version to be published.
Research funding: This work was supported by the Danish National Research Foundation [Funder Id: http://dx.doi.org/10.13039/501100001732, Grant Number: DNRF126] (CHIP & PERSIMUNE), The Lundbeck Foundation, and the Idella Foundation.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare: Dr. Jensen reports travelling to medical congress in 2016 with Roche Pharmaceutical and 2017 with Boehringer-Ingelheim. Other than this, Dr. Jensen has no conflicts of interest. Our institution received reagents for HA from Corgenix Inc, CO, USA. No financial funding was received from any company. All authors declare: no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.